| Ytd | -2.63% | |
| 1y | -26.01% |
| Open | 40.38 | Prev Close | 40.80 | Low | 40.38 | High | 42.38 | Mkt Cap | 1.41B |
| Vol | 1.17M | Avg Vol | 1.07M | EPS | -17.58 | P/E | N/A | Forward P/E | -4.04 |
| Beta | 1.27 | Short Ratio | 8.82 | Inst. Own | 107.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 67.07 | 200-d Avg | 65.30 | 1yr Est | 141.40 |
NKTR News
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintain
Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and S
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintain
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegalde
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintain
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintain